SLC5A2 and heart failure: Another meta-analysis [45] suggested that SGLT2 inhibitor and GLP-1 RA combination therapy was associated with a lower risk of MACE, a composite outcome of hospitalisation for heart failure, cardiovascular mortality and all-cause mortality.